Back to Search
Start Over
Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Table S1- Tumor response by RECIST criteria. Table S2- Treatment details and reasons for discontinuation.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....04a6907f54d47ccf983238e8a3eb7ab9
- Full Text :
- https://doi.org/10.1158/1078-0432.22472835